Results: The 441 patients had the following baseline characteristics: mean age 45±14 years, 71% male, 44% abnormal ALT, 74% HBeAg-negative and 33% advanced fibrosis (METAVIR F3-F4). 59% of patients were treatment-experienced. Overall VR was 94% at 2 years. Naïve patients had similar VR to treatment-experienced patients after 2 years (96% vs 93%, p=NS). To date, HBsAg-loss was observed in 1 1 patients at 2 years. The rate of adverse events (AE) was 14%. No major safety issues were reported.
Liver-related complications were observed in 3 patients (2 cases of hepatocellular carcinoma, 1 episode of spontaneous
bacterial Target Selective Inhibitor Library peritonitis). Ipatasertib solubility dmso Forty-nine elderly patients were subsequently analyzed: mean age 71 ±6 years, 73% male, 35% hypertension, 1 8% diabetes, 87% HBeAg-negative, 58% advanced fibrosis and 80% treatment-experienced. VR did not differ between elderly and younger patients (92% vs 94%, p=NS) at 2 years. AE rate in elderly was 14%. The most common AE was nausea (n=3). Although 82% of elderly had prior estimated glomerular filtration rate < 90mL/min (eGFR estimated by CKD-EPI formula), the mean eGFR remained stable: 72, 69 and 70 mL/min at baseline, 1 and 2 years. In addition, elderly patients with hypertension had stable mean eGFR: 62, 60 and 66 mL/min at baseline, 1 and 2 years. Similar results were observed medchemexpress in elderly patients with diabetes where the mean eGFR was
72, 74 and 80 mL/min at baseline, 1 and 2 years. Conclusions: TDF treatment in clinical practice was associated with a high virologic response, in accordance with phase III studies. In older patients with comorbidities, such as hypertension and diabetes, TDF treatment presented a favorable safety profile. Disclosures: Fabien Zoulim – Advisory Committees or Review Panels: Gilead; Consulting: Roche; Grant/Research Support: Gilead, Scynexis, Roche; Speaking and Teaching: Novartis, Roche, Janssen, Bristol Myers Squibb, Gilead Christophe Hezode – Speaking and Teaching: Roche, BMS, MSD, Janssen, abb-vie, Gilead Georges-Philippe Pageaux – Advisory Committees or Review Panels: Roche, Roche, Roche, Roche; Board Membership: Astellas, Astellas, Astellas, Astellas Xavier Causse – Board Membership: Gilead, BMS, MSD, Janssen-Cilag; Speaking and Teaching: Roche, Gilead, BMS, Janssen-Cilag Dominique G.